Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and
tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
Phase:
Phase 1
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
National Cancer Institute (NCI) TetraLogic Pharmaceuticals